20/20 Biolabs, Inc.
AIDX- Exchange
- Nasdaq
- Industry
- Services-Testing Laboratories
- SEC CIK
- 0001139685
No open-market purchases or sales by 20/20 Biolabs, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $297.1K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by 20/20 Biolabs, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for 20/20 Biolabs, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Bergman Alan B. | Chief Financial Officer | – | Apr 6, 2026 | 1 |
| Zhou Jiming | Chief Operating Officer | – | Apr 6, 2026 | 1 |
| Cohen Jonathan M | Chief Executive Officer | – | Mar 4, 2026 | 1 |
| Cohen Richard M | Director | 7,700 | Feb 23, 2026 | 1 |
| Compton John G. | Director | 14,335 | Feb 23, 2026 | 1 |
| Ross Michael A. | Director | 31 | Feb 23, 2026 | 1 |
| Rollins John Woodson | Director | 30,275 | Feb 23, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.